ArticleOncogene2002
Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer.
Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 87 citations in OpenAlex.
- Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.PLoS medicine · 2016Trial
- Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.Breast cancer research : BCR · 2012Trial
- WDFY4 gene polymorphisms (rs11101565 and rs2671702) are not associated with breast cancer risk in Bangladeshi women: a case-control study.BMC research notes · 2026Article
- Molecular and socioeconomic characteristics of inflammatory breast cancer in the Carolina Breast Cancer Study.Breast cancer research and treatment · 2026Article
- Genetic association ofOncoTargets and therapy · 2019Article
- Good Guy or Bad Guy? The Duality of Wild-Type p53 in Hormone-Dependent Breast Cancer Origin, Treatment, and Recurrence.Cancers · 2018Review
- Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients.Breast cancer research and treatment · 2017Article
- Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation.Journal of Cancer · 2017Article
- Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.Clinical breast cancer · 2016Article
- Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer.Cancer epidemiology · 2016Article
- A simplicial complex-based approach to unmixing tumor progression data.BMC bioinformatics · 2015Article
- TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients.Breast cancer research : BCR · 2014Article
- How do I treat inflammatory breast cancer?Current treatment options in oncology · 2013Article
- Estrogen receptor prevents p53-dependent apoptosis in breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008.Breast cancer research and treatment · 2012Article
- Association of inflammatory and noninflammatory breast cancer with socioeconomic characteristics in the Surveillance, Epidemiology, and End Results database, 2000-2007.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2012Article
- TP53 status and response to treatment in breast cancers.Journal of biomedicine & biotechnology · 2011Review
- Molecular targets for treatment of inflammatory breast cancer.Nature reviews. Clinical oncology · 2009Review
- Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry.Breast cancer research : BCR · 2009Article
- Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer.British journal of cancer · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. We studied the biological characteristics of these tumours by comparing the overexpression of oncogenes ERBB2, MYC, CCND1 and RHOC and TP53 gene mutation rates in IBC with those found in locally advanced and not otherwise specified breast cancers. The prevalence of the TP53 mutation was much higher in IBC than in the two other types of cancer (57% vs 30). Unexpectedly, however, in IBC tumours, histological grade was independent of TP53 status. In addition, ERBB2 overexpression was twice as frequent in inflammatory as in non-inflammatory tumours, whereas the frequencies of MYC, CCND1 and RHOC overexpression did not vary significantly among the three types of breast cancer. These findings suggest that IBC tumours constitute a distinct subset with a specific pathogenesis. Given the importance of TP53 and ERBB2 in the response to treatments, our observations have important therapeutic implications for the clinical management of IBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.